医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Validant Acquires IDEC, a Leading Regulatory Consultancy in Japan

2020年12月01日 AM08:00
このエントリーをはてなブックマークに追加


 

SAN FRANCISCO & TOKYO

Validant, a leading transatlantic quality, compliance and regulatory consulting group (‘the Group’), has acquired IDEC, a leading regulatory consultancy in Japan. IDEC supports customers from across the globe and helps them navigate the Japanese market by providing strategic advice and hands-on implementation support.

IDEC is uniquely positioned to support international and local customers operate in a complex and challenging regulatory environment. The business is led by CEO, Naoya Kato, and a team of highly experienced regulatory affairs professionals with an international background. IDEC provides a full service regulatory and commercialization offering allowing customers to have a virtual presence in Japan. This model allows for a more strategic and efficient process for firms looking to enter the Japanese market.

Validant’s acquisition of IDEC is another important step in its international growth strategy, focused on combining best-in-class regulatory and quality providers, and accelerating their growth with further investment. It follows the acquisition of DataRevive in 2019, a regulatory strategy and consultancy for global clients, based in Washington D.C.

The combination expands the Group’s geographic presence with an office in Tokyo and, together with DataRevive, which recently established a Chinese office, creates a strong base to establish a broader Asian regulatory practice.

Commenting on the announcement, Brian Burns, CEO of Validant said: “We are delighted to announce the acquisition of IDEC and welcome Naoya Kato and his team into the Validant family. Today’s announcement is another important milestone to achieving our ambition to extend our position as the leading quality, compliance and regulatory consulting firm in the healthcare sector globally, as we integrate IDEC’s leading expertise in the Japanese market into the wider Validant offering.”

Chris Brünger, Founder and Chairman of IDEC, said: “It is an exciting time for IDEC to be joining forces with Validant, a company that shares our philosophy and approach in providing the highest quality services to support customers with complex regulatory needs.”

Naoya Kato, CEO of IDEC, said: “It is our pleasure to start a new era as a member of the Validant family to establish a truly global regulatory consulting platform. I look forward to working with the Validant team to combine our expertise and networks to maximize the potential of the business, grow our customer base, and provide the highest value through strategic advice and support of regulatory, clinical, and commercial implementation for speedy development and a successful global product launch.”

- ENDS -

About Validant

Validant is a leading international Quality, Compliance, and Regulatory consulting firm, blending industry expertise with innovation to create custom solutions for companies on the frontier of health. With deep experience working within and alongside the FDA and other regulatory agencies, we understand how to navigate the complexities facing today’s healthcare industry. For further information, please visit www.validant.com

About IDEC

Founded in 2003, IDEC Inc. has ever since enabled its clients to develop and obtain regulatory approval for their innovative treatments in Japan without significant delay compared to the US and EU.

The IDEC team of experts understands the challenges of developing drugs for Japan, both on a standalone basis and through partnerships, and can assist our clients design and implement new strategies for Japan.

IDEC offers its professional services as the “Virtual Japan Team” for its clients, focusing on providing high value-added R&D and market access services. IDEC also provides hands-on implementation to lead Japanese development programs. Please visit www.idec-inc.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005631/en/

CONTACT

For more information please contact:

Instinctif Partners

Agnes Stephens – agnes.stephens@instinctif.com

Ross Gillam – ross.gillam@instinctif.com

Nick Corrin – nick.corrin@instinctif.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024